HIV PEP drugs: Isentress® (Raltegravir) intergrase inhibitor

Isentress┬« is one of the newest classes of antiretrovirals, the intergrase inhibitors. This drug disables the HIV intergrase protein which is responsible for integrating the viral genome into the human chromosome and causing the chronic incurable infection. Developed by Merck and Co, it was approved for adult use in 2007 by the FDA and use… Continue reading